Eli Lilly and Company (LLY) research: valuation against peers, fundamentals over time, risk and news coverage
Guidance reliability · LLYmethodology·all companies
Only 0 resolved quarters on record — below the 6-period threshold, so no verdict is published.
n = 0 resolved forecasts · 55 on record, none yet resolved
Insufficient sample — no verdict published. LLY has 0 resolved forecasts on record, below the 6 needed before we will characterise a management team’s forecasting. The record below is published in full; the company is excluded from every ranking on this site until it clears the threshold.
Next report expected 29 Oct 2026 (Q3 FY2026) — Estimated from the issuer's own filing history: FY2025Q3 results were released on 2025-10-30. source
The record — 55 forecasts, 14 scoredevery figure sourced
| Period | Measure | Guided | Issued | Reported | Landed | Deviation | Verdict | Sources |
|---|---|---|---|---|---|---|---|---|
| FY 2026revised | EPS (adj.) | $35.50–$36.50 | 2026-08-05 | — | — | — | PENDING | guidance |
| “Earnings per Share(1)(3)(4) $35.50 to $37.00 $35.50 to $36.50” | ||||||||
| FY 2026revised | Revenue | $85.00–$87.00bn | 2026-08-05 | — | — | — | PENDING | guidance |
| “Revenue $82 to $85 billion $85 to $87 billion” | ||||||||
| FY 2026revised | EPS (adj.) | $35.50–$37.00 | 2026-04-30 | — | — | — | PENDING | guidance |
| “Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00.” | ||||||||
| FY 2026revised | Revenue | $82.00–$85.00bn | 2026-04-30 | — | — | — | PENDING | guidance |
| “Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00.” | ||||||||
| FY 2026 | EPS (adj.) | $33.50–$35.00 | 2026-02-04 | — | — | — | PENDING | guidance |
| “Earnings per Share(2)(3)(4) $33.50 to $35.00” | ||||||||
| FY 2026 | Revenue | $80.00–$83.00bn | 2026-02-04 | — | — | — | PENDING | guidance |
| “Revenue $80 to $83 billion” | ||||||||
| FY 2025revised | EPS (adj.) | $23.00–$23.70 | 2025-10-30 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance has been increased to be in the range of $21.80 to $22.50 on a reported basis and $23.00 to $23.70 on a non-GAAP basis.” | ||||||||
| FY 2025revised | EPS | $21.80–$22.50 | 2025-10-30 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance has been increased to be in the range of $21.80 to $22.50 on a reported basis and $23.00 to $23.70 on a non-GAAP basis.” | ||||||||
| FY 2025revised | Revenue | $63.00–$63.50bn | 2025-10-30 | — | — | — | PENDING | guidance |
| “The company has increased full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion, primarily driven by strong underlying business performance across the portfolio and foreign exchange rates.” | ||||||||
| FY 2025revised | EPS (adj.) | $21.75–$23.00 | 2025-08-07 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance increased to the range of $20.85 to $22.10 on a reported basis and $21.75 to $23.00 on a non-GAAP basis.” | ||||||||
| FY 2025revised | EPS | $20.85–$22.10 | 2025-08-07 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance increased to the range of $20.85 to $22.10 on a reported basis and $21.75 to $23.00 on a non-GAAP basis.” | ||||||||
| FY 2025revised | Revenue | $60.00–$62.00bn | 2025-08-07 | — | — | — | PENDING | guidance |
| “Full year guidance increased to the range of $60.0 billion to $62.0 billion, primarily driven by strong underlying business performance across the portfolio and foreign exchange rates.” | ||||||||
| FY 2025revised | EPS (adj.) | $20.78–$22.28 | 2025-05-01 | — | — | — | PENDING | guidance |
| “Guidance for EPS for 2025 decreased to the range of $20.17 to $21.67 on a reported basis, driven by the acquired IPR&D charges and net losses on investments in equity securities and $20.78 to $22.28 on a non-GAAP basis, driven by the acquired IPR&D charges.” | ||||||||
| FY 2025revised | EPS | $20.17–$21.67 | 2025-05-01 | — | — | — | PENDING | guidance |
| “Guidance for EPS for 2025 decreased to the range of $20.17 to $21.67 on a reported basis, driven by the acquired IPR&D charges and net losses on investments in equity securities and $20.78 to $22.28 on a non-GAAP basis, driven by the acquired IPR&D charges.” | ||||||||
| FY 2025revised | Revenue | $58.00–$61.00bn | 2025-05-01 | — | — | — | PENDING | guidance |
| “The company reaffirms its previous 2025 revenue guidance and expects it to be between $58.0 billion and $61.0 billion.” | ||||||||
| FY 2025 | EPS (adj.) | $22.50–$24.00 | 2025-02-06 | — | — | — | PENDING | guidance |
| “EPS for 2025 is expected to be in the range of $22.05 to $23.55 on a reported basis and $22.50 to $24.00 on a non-GAAP basis.” | ||||||||
| FY 2025 | EPS | $22.05–$23.55 | 2025-02-06 | — | — | — | PENDING | guidance |
| “EPS for 2025 is expected to be in the range of $22.05 to $23.55 on a reported basis and $22.50 to $24.00 on a non-GAAP basis.” | ||||||||
| FY 2025revised | Revenue | $58.00–$61.00bn | 2025-02-06 | — | — | — | PENDING | guidance |
| “The company anticipates 2025 revenue to be between $58.0 billion and $61.0 billion.” | ||||||||
| FY 2025 | Revenue | $58.00–$61.00bn | 2025-01-14 | — | — | — | PENDING | guidance |
| “The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue” | ||||||||
| FY 2024revised | EPS (adj.) | $13.02–$13.52 | 2024-10-30 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance has been lowered to the ranges of $12.05 to $12.55 on a reported basis and $13.02 to $13.52 on a non-GAAP basis.” | ||||||||
| FY 2024revised | EPS | $12.05–$12.55 | 2024-10-30 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance has been lowered to the ranges of $12.05 to $12.55 on a reported basis and $13.02 to $13.52 on a non-GAAP basis.” | ||||||||
| FY 2024revised | Revenue | $45.40–$46.00bn | 2024-10-30 | — | — | — | PENDING | guidance |
| “The company updated 2024 full-year revenue guidance to between $45.4 billion and $46.0 billion.” | ||||||||
| FY 2024revised | EPS (adj.) | $16.10–$16.60 | 2024-08-08 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance increased to the ranges of $15.10 to $15.60 on a reported basis and $16.10 to $16.60 on a non-GAAP basis.” | ||||||||
| FY 2024revised | EPS | $15.10–$15.60 | 2024-08-08 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance increased to the ranges of $15.10 to $15.60 on a reported basis and $16.10 to $16.60 on a non-GAAP basis.” | ||||||||
| FY 2024revised | Revenue | $45.40–$46.60bn | 2024-08-08 | — | — | — | PENDING | guidance |
| “2024 full-year revenue guidance increased by $3.0 billion to the range of $45.4 billion to $46.6 billion, primarily driven by the strong performance of Mounjaro and Zepbound, as well as the company's non-incretin medicines.” | ||||||||
| FY 2024revised | EPS (adj.) | $13.50–$14.00 | 2024-04-30 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance increased to the range of $13.05 to $13.55 on a reported basis and $13.50 to $14.00 on a non-GAAP basis.” | ||||||||
| FY 2024revised | EPS | $13.05–$13.55 | 2024-04-30 | — | — | — | PENDING | guidance |
| “Based on these changes, EPS guidance increased to the range of $13.05 to $13.55 on a reported basis and $13.50 to $14.00 on a non-GAAP basis.” | ||||||||
| FY 2024revised | Revenue | $42.40–$43.60bn | 2024-04-30 | — | — | — | PENDING | guidance |
| “2024 full-year revenue guidance increased by $2.0 billion to the range of $42.4 billion to $43.6 billion, primarily driven by the strong performance of Mounjaro and Zepbound and greater visibility into the company's production expansion for the remainder of the year.” | ||||||||
| FY 2024 | EPS (adj.) | $12.20–$12.70 | 2024-02-06 | — | — | — | PENDING | guidance |
| “EPS for 2024 is expected to be in the range of $11.80 to $12.30 on a reported basis and $12.20 to $12.70 on a non-GAAP basis.” | ||||||||
| FY 2024 | EPS | $11.80–$12.30 | 2024-02-06 | — | — | — | PENDING | guidance |
| “EPS for 2024 is expected to be in the range of $11.80 to $12.30 on a reported basis and $12.20 to $12.70 on a non-GAAP basis.” | ||||||||
| FY 2024 | Revenue | $40.40–$41.60bn | 2024-02-06 | — | — | — | PENDING | guidance |
| “The company anticipates 2024 revenue to be in the range of $40.4 billion to $41.6 billion.” | ||||||||
| FY 2023revised | EPS (adj.) | $6.50–$6.70 | 2023-11-02 | — | — | — | PENDING | guidance |
| “2023 reported EPS guidance lowered to the range of $5.95 to $6.15 and non-GAAP EPS guidance lowered to the range of $6.50 to $6.70, both primarily driven by the acquired IPR&D charges incurred in Q3.” | ||||||||
| FY 2023revised | EPS | $5.95–$6.15 | 2023-11-02 | — | — | — | PENDING | guidance |
| “2023 reported EPS guidance lowered to the range of $5.95 to $6.15 and non-GAAP EPS guidance lowered to the range of $6.50 to $6.70, both primarily driven by the acquired IPR&D charges incurred in Q3.” | ||||||||
| FY 2023revised | Revenue | $33.40–$33.90bn | 2023-11-02 | — | — | — | PENDING | guidance |
| “Revenue guidance remains unchanged with the range of $33.4 to $33.9 billion.” | ||||||||
| FY 2023revised | EPS (adj.) | $9.70–$9.90 | 2023-08-08 | — | — | — | PENDING | guidance |
| “2023 reported EPS guidance raised $1.02 to the range of $9.20 to $9.40 and non-GAAP EPS guidance raised $1.05 to the range of $9.70 to $9.90.” | ||||||||
| FY 2023revised | EPS | $9.20–$9.40 | 2023-08-08 | — | — | — | PENDING | guidance |
| “2023 reported EPS guidance raised $1.02 to the range of $9.20 to $9.40 and non-GAAP EPS guidance raised $1.05 to the range of $9.70 to $9.90.” | ||||||||
| FY 2023revised | Revenue | $33.40–$33.90bn | 2023-08-08 | — | — | — | PENDING | guidance |
| “Revenue guidance increased by $2.2 billion to the range of $33.4 to $33.9 billion.” | ||||||||
| FY 2023revised | Revenue | $30.30–$30.80bn | 2023-02-02 | — | — | — | PENDING | guidance |
| “Revenue $30.3 to $30.8 billion Unchanged” | ||||||||
| FY 2023revised | EPS (adj.) | $8.35–$8.55 | 2023-02-02 | — | — | — | PENDING | guidance |
| “2023 EPS guidance updated to be in the range of $7.90 to $8.10 on a reported basis and $8.35 to $8.55 on a non-GAAP basis.” | ||||||||
| FY 2023revised | EPS | $7.90–$8.10 | 2023-02-02 | — | — | — | PENDING | guidance |
| “2023 EPS guidance updated to be in the range of $7.90 to $8.10 on a reported basis and $8.35 to $8.55 on a non-GAAP basis.” | ||||||||
| FY 2023 | EPS (adj.) | $8.10–$8.30 | 2022-12-13 | — | — | — | PENDING | guidance |
| “2023 EPS expected to be in the range of $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.” | ||||||||
| FY 2023 | EPS | $7.65–$7.85 | 2022-12-13 | — | — | — | PENDING | guidance |
| “2023 EPS expected to be in the range of $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.” | ||||||||
| FY 2023 | Revenue | $30.30–$30.80bn | 2022-12-13 | — | — | — | PENDING | guidance |
| “2023 revenue expected to be between $30.3 billion and $30.8 billion, driven by key growth products.” | ||||||||
| FY 2022revised | EPS (adj.) | $7.70–$7.85 | 2022-12-13 | — | — | — | PENDING | guidance |
| “Earnings per share (non-GAAP) $7.70 to $7.85 4% to 6%” | ||||||||
| FY 2022revised | EPS | $6.50–$6.65 | 2022-12-13 | — | — | — | PENDING | guidance |
| “Earnings per share (reported) $6.50 to $6.65 6% to 9%” | ||||||||
| FY 2022revised | Revenue | $28.50–$29.00bn | 2022-12-13 | — | — | — | PENDING | guidance |
| “Revenue $28.5 to $29.0 billion” | ||||||||
| FY 2022revised | Revenue | $28.50–$29.00bn | 2022-11-01 | — | — | — | PENDING | guidance |
| “The company now anticipates 2022 revenue to be between $28.5 billion and $29.0 billion.” | ||||||||
| FY 2022revised | EPS (adj.) | $7.70–$7.85 | 2022-11-01 | — | — | — | PENDING | guidance |
| “2022 EPS guidance updated to be in the range of $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis, both inclusive of $0.67 of acquired IPR&D and development milestone charges.” | ||||||||
| FY 2022revised | EPS | $6.50–$6.65 | 2022-11-01 | — | — | — | PENDING | guidance |
| “2022 EPS guidance updated to be in the range of $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis, both inclusive of $0.67 of acquired IPR&D and development milestone charges.” | ||||||||
| FY 2022revised | EPS (adj.) | $7.90–$8.05 | 2022-08-04 | — | — | — | PENDING | guidance |
| “EPS for 2022 is now expected to be in the range of $6.96 to $7.11 on a reported basis and $7.90 to $8.05 on a non-GAAP basis.” | ||||||||
| FY 2022revised | EPS | $6.96–$7.11 | 2022-08-04 | — | — | — | PENDING | guidance |
| “EPS for 2022 is now expected to be in the range of $6.96 to $7.11 on a reported basis and $7.90 to $8.05 on a non-GAAP basis.” | ||||||||
| FY 2022revised | Revenue | $28.80–$29.30bn | 2022-08-04 | — | — | — | PENDING | guidance |
| “The company still anticipates 2022 revenue to be between $28.8 billion and $29.3 billion.” | ||||||||
| FY 2022 | EPS (adj.) | $8.15–$8.30 | 2022-04-28 | — | — | — | PENDING | guidance |
| “2022 EPS guidance updated to be in the range of $7.30 to $7.45 on a reported basis and $8.15 to $8.30 on a non-GAAP basis, both inclusive of $0.55 of acquired IPR&D and development milestone charges.” | ||||||||
| FY 2022 | EPS | $7.30–$7.45 | 2022-04-28 | — | — | — | PENDING | guidance |
| “2022 EPS guidance updated to be in the range of $7.30 to $7.45 on a reported basis and $8.15 to $8.30 on a non-GAAP basis, both inclusive of $0.55 of acquired IPR&D and development milestone charges.” | ||||||||
| FY 2022 | Revenue | $28.80–$29.30bn | 2022-04-28 | — | — | — | PENDING | guidance |
| “The company now anticipates 2022 revenue to be between $28.8 billion and $29.3 billion.” | ||||||||
Every figure above is read from the company’s own filings. “Guidance” links to the 8-K exhibit that issued the forecast; “result” links to the exhibit in which the company reported the outcome. Nothing here is an analyst estimate. How this is measured.
Coverage universe: S&P 100. This is a factual record of what a company forecast and what it then reported. It is not investment advice, and it is not a view on the company’s prospects — we publish the measurement and draw no conclusion from it.
ChartVs peersValuationValue mapQuartersScaleMarginsTrajectoryCash qualityPer shareReinvestmentBalance sheetStreetRiskSeasonalityOur coverage
LLY
Eli Lilly and CompanyUSD
1,160
+0.28% today
Market cap
—
P/E trailing
—
P/E forward
—
EV/EBITDA
—
Op margin
—
Rev growth
—
Div yield
—
Beta
—
52-week range714.59 – 1,280.34
Price navigator — LLY
No data in this window.
What LLY trades with
The themes this instrument belongs to, and the rest of what sits inside them — the peer set a screener gives you is statistical, this one is editorial.
Obesity drugs & pharma
The GLP-1 duopoly, the challengers, and the sector they have been carrying.
INDY NEWS coverage of LLY0
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
Nothing filed on LLY yet. Search the archive for related coverage.
Full archive search for LLYEvery figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.